UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~October~~November 2025

Commission File Number 001-42688

707 Cayman Holdings Limited

(Exact name of registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s Name Into English)

5/F., AIA Financial Centre 712 Prince Edward Road East San Po Kong, Kowloon, Hong Kong (Address of principal executive offices) (Zip Code)

5/F, AIA Financial Centre, 712 Prince Edward Road East, San Po Kong		Hong Kong
(Address of principal executive offices)		(Zip Code)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

~~Indicate~~Entry byinto ~~check~~a ~~mark~~Material ifDefinitive ~~the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____~~Agreement

~~Indicate~~On byNovember ~~check~~20, ~~mark~~2025, if707 Cayman Holdings Limited (the ~~registrant~~“Company”) isentered ~~submitting~~into an Equity Purchase Agreement (“Equity Purchase Agreement”) with Hudson Global Ventures, LLC (the ~~Form~~“Investor”) ~~6-K~~pursuant into ~~paper~~which asthe ~~permitted~~Company bywill have ~~Regulation~~the ~~S-T~~right, ~~Rule~~but ~~101~~not the obligation to sell to the Investor, and the Investor will have the obligation to purchase from the Company up to US$18,000,000 worth of the Company’s ordinary shares (bthe “Put Shares”) at the Company’s sole discretion over the next 24 months, subject to certain conditions precedent and other limitations. Concurrently with the execution of the Equity Purchase Agreement, the Company agreed to issue 750,360 of the Company’s ordinary shares (7the “Commitment Shares”): to ~~____~~the Investor as part of the consideration. A copy of the Equity Purchase Agreement is attached hereto as Exhibit 10.1 and is incorporated herein by reference. The foregoing description of the Equity Purchase Agreement is a summary of the material terms of such agreement, and does not purport to be complete and is qualified in its entirety by reference to the Equity Purchase Agreement.

~~Indicate~~On bythe ~~check~~same ~~mark~~date, ~~whether~~ the ~~registrant~~Company byalso ~~furnishing~~entered ~~the~~into ~~information~~a ~~contained~~registration inrights ~~this~~agreement ~~Form~~(the is“Registration ~~also~~Rights ~~thereby~~Agreement”) with ~~furnishing~~the Investor, pursuant to which the ~~information~~ Company agreed to submit to the U.S. Securities and Futures Commission ~~pursuant~~(the to“SEC”) an ~~Rule~~initial ~~12g3~~registration statement on Form F-21 (bthe registration statement, as amended, the “Registration Statement”) by December 20, 2025 covering the resale of the Commitment Shares and Put Shares, which may have been, or which may from time to time be, issued under the ~~Securities~~Equity ~~Exchange~~Purchase ~~Act~~Agreement offor ~~1934:~~public resale, and to use its reasonable best efforts to cause the Registration Statement to be declared effective by the SEC.

~~Yes~~A ☐copy Noof ☒the Registration Rights Agreement is attached hereto as Exhibit 10.2 and is incorporated herein by reference. The foregoing description of the Registration Rights Agreement is a summary of the material terms of such agreement, and does not purport to be complete and is qualified in its entirety by reference to the Registration Rights Agreement.

IfThe ~~“Yes”~~Equity isPurchase ~~marked~~Agreement and Registration Rights Agreement contain customary representations, ~~indicate~~warranties ~~below~~and agreements by the ~~file~~Company and ~~number~~customary ~~assigned~~conditions to the ~~registrant~~Investor’s inobligation ~~connection~~to ~~with~~purchase ~~Rule~~the ~~12g3-2(b):~~Put Shares. They are contractual documents that establish and govern the legal relations between the Company and the Investor and are not intended to be a source of factual, business or operational information about the Company for other investors and potential investors of the Company.

~~Nasdaq~~Forward-Looking ~~Minimum Bid Price Deficiency Letter~~Statements

OnMatters ~~October~~discussed 17in this report may constitute forward-looking statements. Forward-looking statements include statements concerning plans, ~~2025~~objectives, goals, ~~707~~strategies, ~~Cayman~~future ~~Holdings~~events ~~Limited~~or ~~(the~~performance, ~~“Company”)~~and ~~received~~underlying aassumptions ~~letter~~and ~~from~~other ~~the~~statements, ~~Listing~~other ~~Qualifications~~than ~~staff~~statements of historical facts. The ~~Nasdaq~~words ~~Stock~~“believe,” ~~Market~~“anticipate,” (“~~Nasdaq~~intends,”) ~~notifying~~“estimate,” ~~the~~“potential,” “may,” ~~Company~~“should,” ~~that~~“expect” ~~based~~“pending” onand ~~the~~similar ~~closing~~expressions ~~bid~~identify ~~price~~forward-looking statements. ofThe ~~the~~forward-looking ~~Company~~statements ~~for~~in ~~the~~this ~~period~~report are based upon various assumptions. Although we believe that these assumptions ~~from~~were ~~September~~reasonable 3when made, ~~2025~~because tothese ~~October~~assumptions ~~16,~~are ~~2025,~~inherently ~~the~~subject ~~Company~~to nosignificant ~~longer~~uncertainties ~~meets~~and ~~the~~contingencies ~~continued~~which ~~listing~~are difficult ~~requirement~~or ofimpossible ~~Nasdaq~~to ~~under~~predict ~~Nasdaq~~and ~~Listing Rules~~are ~~5550(a)(2)~~beyond our control, towe ~~maintain~~cannot aassure ~~minimum~~you ~~bid~~that ~~price~~we ofwill $1achieve ~~per~~or ~~share~~accomplish these expectations.

Nasdaq has provided the Company with a 180-calendar day compliance period, or until April 15, 2026, in which to regain compliance with Nasdaq continued listing requirement. In the event that the Company does not regain compliance in the compliance period, the Company may be eligible for an additional 180 calendar days, should the Company meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and is able to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company’s securities will be subject to delisting.

The Company is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirement. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement.

On October 21, 2025, the Company issued a press release discussing the receipt of the deficiency letter, which is filed as exhibit 99.1 to this Form 6-K.

Exhibits

99.1 Press Release on Receipt of Nasdaq Deficiency Letter dated October 21, 2025

99.1		Equity Purchase Agreement dated November 20, 2025 between the Company and Hudson Global, LLC
99.2		Registration Rights Agreement between the Company and Hudson Global LLC dated November 20, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	707 Cayman Holdings Limited
Date: October 21, 2025	By	/s/ Cheung Lui
Date: November 25, 2025	By	/s/ Cheung Lui
		Cheung Lui
		Chief Executive Officer and Executive Director
		Chief Executive Officer

Filing Compare · 707 Cayman Holdings Ltd.